LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Roivant Sciences Ltd

Closed

SectorHealthcare

14.08 -2.22

Overview

Share price change

24h

Current

Min

14.08

Max

14.21

Key metrics

By Trading Economics

Income

-22M

-274M

Sales

-5.4M

2.2M

EPS

-0.29

Profit margin

-12,622.627

Employees

750

EBITDA

-284K

-284M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+15.7% upside

Market Stats

By TradingEconomics

Market Cap

1.2B

8.8B

Previous open

16.3

Previous close

14.08

News Sentiment

By Acuity

50%

50%

148 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 wrz 2025, 22:41 UTC

Major Market Movers

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 wrz 2025, 16:04 UTC

Major Market Movers

Upexi Shares Climb on Solana Gains

14 wrz 2025, 23:48 UTC

Market Talk

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 wrz 2025, 23:41 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 wrz 2025, 23:38 UTC

Market Talk

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 wrz 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 wrz 2025, 23:13 UTC

Market Talk

Global Energy Roundup: Market Talk

14 wrz 2025, 23:13 UTC

Market Talk

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 wrz 2025, 23:13 UTC

Market Talk

Global Equities Roundup: Market Talk

14 wrz 2025, 23:04 UTC

Market Talk

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 wrz 2025, 08:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 wrz 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 wrz 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 wrz 2025, 20:09 UTC

Earnings

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 wrz 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 wrz 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 wrz 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 wrz 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 wrz 2025, 18:38 UTC

Market Talk
Earnings

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 wrz 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 wrz 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 wrz 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 wrz 2025, 16:22 UTC

Earnings

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 wrz 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 wrz 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 wrz 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12 wrz 2025, 16:11 UTC

Earnings

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 wrz 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 wrz 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 wrz 2025, 15:07 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

15.7% upside

12 Months Forecast

Average 16.29 USD  15.7%

High 19 USD

Low 12 USD

Based on 9 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

148 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat